Millions of children in the United States don’t have health coverage. As a result, it may be difficult or impossible for them to get the routine preventive care that keeps them healthy or access to the care they need if they get sick or injured. But, the majority of the nation’s uninsured children are eligible for free or low-cost health coverage through their state Medicaid or Children’s Health Insurance Program (CHIP). They can apply for the comprehensive benefits these programs provide at any time, and now the enrollment process is faster.
To view the multimedia release go to:
https://www.multivu.com/players/English/8102651-hhs-connecting-kids-to-coverage-psa-insurekidsnow/
Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, today announced the launch of seven hematology genetics test panels. The new test panels enhance and expand BloodCenter’s genetic testing capability to include a vast array of non-malignant hematology disorders, including platelet function disorders, inherited thrombocytopenia and congenital neutropenias, providing one of the most comprehensive test menus in hematology.
BloodCenter’s integration of functional and genetic testing provides a unique approach to diagnosing complex hematology disorders, providing a comprehensive review of each patient for improved patient care and outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126851-bloodcenter-of-wisconsin-versiti-hematology-genetics-test-panels/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
Today, WebMD released My Abuelita Told Me, a new five-part video series developed in partnership with Dr. Juan Rivera (“Dr. Juan”), a board-certified internist and cardiologist, who is well-known for his best-selling books and regular appearances on broadcast television. My Abuelita Told Me explores the reliability of the various home remedies, beliefs and established practices that beloved abuelitas (a.k.a. grandmas) have passed down through the generations, and Dr. Juan clarifies what is or isn’t accurate using medical science.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579758-webmd-my-abuelita-told-me-bilingual-video-series/
Blink Health, America’s leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health’s website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.
To view the multimedia release go to:
https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
Allied Universal, a leading facility services company and the largest security force in North America, together with John Jay College and the Metropolitan Healthcare Security Directors Association (MHSDA), will host a “Plan to Live” seminar to educate healthcare providers on best practices to handle an active shooter situation and other threats. The free seminar will be held Tues., May 16, from 9 a.m. to 1:30 p.m. in the college’s Moot Court at 899 10th Avenue, New York City.
“Active shooters are not the only risks that healthcare facilities face,” said Kevin Francis, Business Development Specialist, Allied Universal. “Healthcare facilities may encounter aggressive assailants, bomb threats, and terrorist attacks. Our seminar provides tips and information from leading experts to help them prepare for, survive and recover from an attack.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7883351-allied-universal-john-jay-active-shooter-seminar/
Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Today, Johnson & Johnson, the world’s largest healthcare company, launches Johnson & Johnson Our Story at the Powerhouse and Johnson & Johnson Our Story to take visitors on a journey through time and around the world as they explore the stories behind more than 130 years of innovations that have changed the course of human health.
To view the multimedia release go to:
https://www.multivu.com/players/English/8077331-jnj-our-story/
Sandaire, an international family investment office with a base in Singapore and Delancey, a UK focused real estate advisory company, today launch Mount Kendal in Asia. Mount Kendal is a new collaboration between Delancey and Sandaire and will be focused on delivering bespoke UK real estate investment advice to Asian investors and international family offices.
Together, the two firms bring over 45 years of experience to Mount Kendal, which was established to deliver acquisition strategies and innovative asset management initiatives. Ultimately Mount Kendal seeks to create and protect value across a myriad of multi-sector, single asset or asset portfolio investments; from office, retail, residential and logistics; to healthcare, education, equity reversions and more.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8088051-sandaire-delancey-launch-mount-kendal/
